GLS and neoplasm: Importantly, JHU083, as a DON prodrug, blocks the glutaminase (deamidase) activity of CAD and overcomes the toxicity issues of DON by selectively targeting tumor microenvironment23, demonstrating its therapeutic potential for future clinical evaluation.